PMEF
STLN

Point72 Middle East FZE’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Point72 Middle East FZE’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,226
Closed -$1.77K – 1876
2023
Q2 		$1.77K Buy
+3,226
New +$1.71K ﹤0.01% 1467

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Point72 Middle East FZE's STLN Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q3 2023, closing a stake of 3,226 shares — an estimated $1.77K sold.

Point72 Middle East FZE first reported a position in STLN in Q2 2023 and held it in 1 quarter. The position peaked at $1.77K in Q2 2023. 36 funds tracked by Wall St. Rank hold STLN as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,226 Starling Oncology Institute, Inc. Common Stock shares in Q3 2023, an estimated $1.77K.
  • Point72 Middle East FZE first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Starling Oncology Institute, Inc. Common Stock position peaked at $1.77K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.